News
But within weeks, Novo Nordisk’s partnership crumbled amid a messy war of words. Novo Nordisk accused Hims & Hers of continuing to deceptively sell large volumes of copycat vers ...
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...
KWKT - FOX 44 on MSN4h
New tariffs could raise prices of Ozempic, WegovySome of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
CNBC's Karen Gilchrist discusses Novo Nordisk's new CEO and the pharma giant's move to cut its full-year guidance on weaker ...
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback